Skip to main content

Table 1 Baseline characteristics of the study population, analyzed separately according to the presence or absence of VAs

From: Identification of patients with nonischemic dilated cardiomyopathy at risk of malignant ventricular arrhythmias: insights from cardiac magnetic resonance feature tracking

Variable

All Patients (n = 263)

NIDCM with VAs (n = 61)

NIDCM without VAs (n = 202)

t/χ2/Z

P value

Age (years)

49 ± 13

48 ± 14

49 ± 13

−0.49

0.62

Sex (male), n (%)

177 (67%)

38 (62%)

139 (69%)

0.01

0.93

BSA (m2)

1.76 (1.62, 1.88)

1.77 (1.47, 1.84)

1.75 (1.59, 1.82)

−0.11

0.61

Heart rate (beata/min)

94 ± 11

109 ± 12

78 ± 13

2.13

< 0.001

Family history, n (%)

51 (19%)

9 (15%)

42 (21%)

0.12

0.08

Diabetes, n (%)

31 (12%)

6 (10%)

25 (12%)

0.07

0.73

Hypertension, n (%)

68 (26%)

15 (25%)

53 (26%)

0.13

0.69

GFR (mL/min)

76 ± 7

74 ± 6

75 ± 8

−6.24

0.35

SCr (µmol/L)

90 ± 11

88 ± 6

89 ± 8

−5.17

0.42

Medical treatment

     

β-blockers, n (%)

195 (74%)

48 (78%)

147 (73%)

2.76

0.04

Amiodarone, n (%)

6 (2%)

6 (10%)

—

—

—

ACE-inhibitors/ARBs, n (%)

203 (77%)

48 (78%)

155 (77%)

0.18

0.52

MRA, n (%)

111 (42%)

26 (43%)

85 (42%)

−3.74

0.32

Diuretic, n (%)

68 (26%)

16 (26%)

52 (26%)

0.36

0.78

Statin, n (%)

103 (39%)

24 (39%)

79 (39%)

0.18

0.69

CMR parameters

     

LVEF (%)

41.61 ± 5.45

40.59 ± 7.83

41.75 ± 6.49

−4.18

0.07

LVEDVI (mL/m2)

189.55 (169.73, 212.34)

190.65 (164.05, 212.10)

188.40 (162.43, 210.81)

−0.76

0.09

LVESVI (mL/m2)

121.73 (104.56, 139.25)

125.15 (110.13, 133.35)

121.26 (101.67, 137.76)

−2.96

0.12

SVI (mL/m2)

40.33 ± 10.28

39.24 ± 9.66

40.19 ± 10.96

−0.29

0.76

CI (L/min/m2)

3.81 (2.71, 4.62)

3.70 (2.81, 4.53)

3.82 (2.63, 4.57)

−0.38

0.70

LGE (+), n (%)

132 (50%)

40 (66%)

92 (46%)

0.46

0.06

Percent LGE (%)

11.26 ± 2.35

15.51 ± 3.30

9.62 ± 2.18

10.39

< 0.001

GPRS (%)

11.46 (9.51, 15.44)

10.59 (8.44, 13.96)

11.66 (9.42, 15.21)

−2.44

0.09

GPCS (%)

−9.01 (− 11.05, − 8.23)

−5.38 (− 7.50, − 4.22)

−9.22 (− 10.73, − 8.19)

−5.56

< 0.01

GPLS (%)

−9.62 ± 2.32

−9.13 ± 2.25

−9.90 ± 2.07

3.64

0.05

  1. Results are reported as mean ± SD, percentages, or median (interquartile range) as appropriate. NIDCM, nonischemic dilated cardiomyopathy; BSA, body surface area; GFR, glomerular filtration rate; SCr, serum creatinine; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular ejection; EDV, end-diastolic volume; ESV, end-systolic volume; SV, Stroke volume; CI, Cardiac index; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; SVI, indexed-stroke volume; LGE (+), late gadolinium enhancement positive; %LGE, LGE (+) mass as percentage of left ventricular myocardial mass; GPRS, global peak radial strain; GPCS, global peak circumferential strain; GPLS, global peak longitudinal strain
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us